Overview

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Status:
Completed
Trial end date:
2015-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study the effect of lanabecestat on how the body absorbs and processes 3 other medications, midazolam, simvastatin and donepezil and how these 3 medications affect lanabecestat when they are taken together. This study is in 2 cohorts, Cohort A is approximately 44 days long and Cohort B about 70 days only. The screening visit is required within 30 days prior to the start on the study
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Eli Lilly and Company
Collaborators:
AstraZeneca
Eli Lilly and Company
Treatments:
Donepezil
Midazolam
Simvastatin